At IDWeek 2026, Akimasa Fukushi from Shionogi presented a subpopulation analysis of the Phase III SCORPIO-PEP trial. This analysis may provide insights into the potential benefits of early ensitrelvir post-exposure prophylaxis (PEP) for both breakthrough and established Covid-19 cases. The findings could have implications for manufacturers and healthcare providers in understanding the efficacy of ensitrelvir in different patient populations.
Source: pharmaceutical-technology.com · Image: PhUSE 2015 CSS – 34 (18164529429) by The U.S. Food and Drug Administration, Public domain, via Wikimedia Commons
Affordable access, full power:
For just $42 per month, the “Solo” plan unlocks the same API & FDF Intelligence data used by global companies.
You instantly see price ranges, dossiers, and certificates — and, most importantly, gain direct contacts to every manufacturer and FDF holder.
It’s a practical way to work with reliable data without heavy budgets.
Get started today with Solo access →
Get started today with Solo access →
